Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 10, 2021 |
Sep. 30, 2023 |
Mar. 31, 2023 |
Dec. 31, 2022 |
Nov. 30, 2022 |
Jul. 31, 2021 |
Mar. 31, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Stock issued (in dollars per share) | $ 55 | $ 35 | $ 113 | ||||||||
| Payment of offering expenses | $ 400 | $ 500 | $ 400 | ||||||||
| Proceeds from issuance of common stock | $ 235,800 | $ 433,200 | $ 551,200 | ||||||||
| Research and development | $ 320,678 | $ 316,415 | $ 264,208 | ||||||||
| Preferred stock, shares authorized | 50,000,000 | ||||||||||
| Preferred stock, shares issued | 0 | ||||||||||
| Preferred stock, shares outstanding | 0 | ||||||||||
| Common stock, shares authorized | 750,000,000 | 750,000,000 | 750,000,000 | ||||||||
| Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
| Common stock, shares issued | 4,550,000 | 111,255,000 | 13,144,500 | 5,175,000 | 119,581,000 | 111,255,000 | |||||
| Common stock, shares outstanding | 111,255,000 | 119,581,000 | 111,255,000 | ||||||||
| In-process research and development acquisition | |||||||||||
| Asset acquisition, consideration | $ 35,600 | $ 15,000 | $ 10,000 | ||||||||
| Issuance of common stock | 276,346 | ||||||||||
| Value of common stock issued | $ 30,900 | $ 10,000 | $ 15,000 | ||||||||
| Cash consideration | 3,900 | ||||||||||
| Net liabilities assumed | 200 | ||||||||||
| Acquisition related costs | 600 | ||||||||||
| Value of additional shares potentially issuable | $ 35,000 | ||||||||||
| Number of additional shares potentially issuable | 269,547 | ||||||||||
| Research and development | $ 35,600 | ||||||||||
| Common stock | |||||||||||
| Common stock, shares issued | 111,255,000 | 119,581,000 | 111,255,000 | 95,140,000 | 86,223,000 | ||||||
| X | ||||||||||
- Definition Number of additional shares potentially issuable as consideration upon achievement of milestones in asset acquisition. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in asset acquisition. No definition available.
|
| X | ||||||||||
- Definition Number of shares issued and issuable as consideration in asset acquisition. No definition available.
|
| X | ||||||||||
- Definition Value of shares reserved for issuance in registration statement. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share or per unit amount of equity securities issued. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|